Top

Published in:

Open Access 01-10-2018 | Original Article

Analysis of Undesirable Sequelae of Sentinel Node Surgery in Breast Cancer Patients – a Prospective Cohort Study

Authors: Dominika Kozak, Iwona Głowacka-Mrotek, Tomasz Nowikiewicz, Zygmunt Siedlecki, Wojciech Hagner, Magdalena Sowa, Wojciech Zegarski

Published in: Pathology & Oncology Research | Issue 4/2018

Abstract

Use of sentinel lymph node biopsy limits the frequency and severity of sequelae of surgical treatment. However, the procedure itself may not be completely free of complications. The goal of this work was to analyze prospectively the occurrence of undesirable sequelae in patients undergoing sentinel lymph node biopsy as an isolated intervention in the axillary fossa. This prospective observational study was conducted on a group of 104 women. Patients were examined on five occasions: one day before the procedure, one day after the procedure, one month, three months, and six months after the procedure. At every stage of the study they were assessed for tactile sensation, range of motion in the shoulder joint, upper limb circumference, sensation abnormalities, winged scapula sign, and pain severity according to Visual Analogue Scale (VAS). In the study group we observed statistically significant differences, such as limited mobility in the shoulder joint (p ≤ 0.01), gradual increase in limb circumference on the operated side (p < 0.01) and pain (p ≤ 0.01). Despite relatively low invasiveness of the procedure, sentinel lymph node biopsy is not entirely devoid of the risk of undesirable sequelae.

Ivens D, Hoe AL, Podd TJ et al (1992) Assessment of morbidity from complete axillarym dissection. Br J Cancer 66(1):136–138CrossRefPubMedPubMedCentral

McWayne J, Heiney SP (2005) Psychologic and social sequelae of secondary lymphedema: a review. Cancer 104(3):457–466. https://doi.org/10.1002/cncr.21195 CrossRefPubMed

Głowacka I, Nowikiewicz T, Siedlecki Z et al (2016) The assessment of the magnitude of frontal plane postural changes in breast cancer patients after breast-conserving therapy or mastectomy - follow-up results 1 year after the surgical procedure. Pathol Oncol Res 22(1):203–208. https://doi.org/10.1007/s12253-015-9995-7 CrossRefPubMed

Albert US, Koller M, Kopp I et al (2006) Early self-reported impairments in arm functioning of primary breast cancer patients predict late side effects of axillary lymph node dissection: results from a population-based cohort study. Breast Cancer Res Treat 100(3):285–292. https://doi.org/10.1007/s10549-006-9247-3 CrossRefPubMed

Belmonte R, Garin O, Segura M et al (2012) Quality-of-life impact of sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients. Value Health 15:907–915. https://doi.org/10.1016/j.jval.2012.06.003 CrossRefPubMed

Del Bianco P, Zavagno G, Burelli P et al (2008) Morbidity comparison of sentinel node biosy versus conventional axillary lymph node dissectionu for breast cancer patients: results of the sentinella-Givom Italia randomised clinical trial. EJSO 34:508–513. https://doi.org/10.1016/j.ejso.2007.05.017 CrossRefPubMed

Kootstra JJ, Hoekstra HJ, Rietman J et al (2010) A longitudinal comparison of arm morbidity in stage I-II breast cancer patients treated with sentinel lymph node biopsy, sentinel lymph node biopsy followed by completion lymph node dissection, or axillary lymph node dissection. Ann Surg Oncol 17:2384–2394. https://doi.org/10.1245/s10434-010-0981-8 CrossRefPubMedPubMedCentral

Land S, Kopec J, Julian T et al (2010) Patient-reported outcomes in sentinel nodenegative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and bowel project phase III protocol B-32. J Clin Oncol 28:3929–3936. https://doi.org/10.1200/JCO.2010.28.2491 CrossRefPubMedPubMedCentral

Schulze T, Mucke J, Markwardt J et al (2006) Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol 29:109–119. https://doi.org/10.1002/jso.20406 CrossRef

10.

Mansel RE, Fallowfield L, Kissin M et al (2006) Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial. Journal of the National Cancer Institute 98(9):599–609. https://doi.org/10.1093/jnci/djj158 CrossRefPubMed

11.

Fleissig A, Fallowfield LJ, Langridge CI et al (2006) Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 95:279–293. https://doi.org/10.1007/s10549-005-9025-7 CrossRefPubMed

12.

Giuliano AE, Haigh PI, Brennan MB et al (2000) Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 18:2553–2559. https://doi.org/10.1200/JCO.2000.18.13.2553 CrossRefPubMed

13.

Purushotham A, Uponi S, Klevesath M et al (2005) Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 23:4312–4321. https://doi.org/10.1200/JCO.2005.03.228 CrossRefPubMed

14.

Liu C, Guo Y, Shi J et al (2009) Late morbidity associated with a tumour-negative sentinel lymph node biopsy in primary breast cancer patients: a systematic review. Eur J Cancer 45:1560–1568. https://doi.org/10.1016/j.ejca.2009.02.012 CrossRefPubMed

15.

Favarao K, Mantse J, Barros A (2010) Shoulder mobility after axillary sentinel lymph node biopsy for early infiltrating breast cancer treatment. European Journal of Gynaecologic Oncology 31:23–26

16.

Hack T, Kwan W, Thomas-MacLean R et al (2010) Predictors of arm morbidity following breast cancer surgery. Psycho-Oncology 19:1205–1212. https://doi.org/10.1002/pon.1685 CrossRefPubMed

17.

Martin RC, Edwards MJ, Wong SL et al (2000) Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. Surgery 128(2):139–144CrossRefPubMed

18.

Berg JW (1955) The significance of axillary node levels in the study of breast carcinoma. Cancer 8:776–778CrossRefPubMed

19.

Peintinger F, Reitsamer R, Stranzl H et al (2003) Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Br J Cancer 89:648–652. https://doi.org/10.1038/sj.bjc.6601150 CrossRefPubMedPubMedCentral

20.

DiSipio T, Rye S, Newman B et al (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. The Lancet Oncology 14(6):500–515. https://doi.org/10.1016/S1470-2045(13)70076-7 CrossRefPubMed

21.

Bulley C, Coutts F, Blyth C et al (2013) Prevalence and impacts of upper limb morbidity after treatment for breast cancer: a cross-sectional study of lymphedema and function. Cancer and Oncology Research 1(2):30–39. https://doi.org/10.1016/j.ejon.2013.10.006 CrossRef

22.

Mc Laughlin S, Wright M, Morris K et al (2008) Prevalence in lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 26(32):5213–5219. https://doi.org/10.1200/JCO.2008.16.3725 CrossRef

23.

Gӧker M, Devoogdt N, Van De Putte G et al (2013) Systematic review of breast cancer related lymphoedema: making a balanced decision to perform an axillary clearance. Facts, Views Vis Obstet Gynaecol 5(2):106–115

24.

Ozcinar B, Guler S, Kocaman N et al (2012) Breast cancer related lymphedema in patients with different loco-regional treatments. Breast 21(3):361–365CrossRefPubMed

25.

Togawa K, Huiyan M, Sullivan-Halley J et al (2014) Risk factors for self-reported arm lymphedema among female breast cancer survivors: a prospective cohort study. Breast Cancer Res 16:414–419. https://doi.org/10.1016/j.breast.2012.03.002 CrossRefPubMedPubMedCentral

26.

Mansel R, MacNeill F, Horgan K et al (2013) Results of a national training programme in sentinel lymph node biopsy for breast cancer. Br J Surg 100:654–661. https://doi.org/10.1002/bjs.9058 CrossRefPubMed

27.

Khavanin N, Gart M, Berry T et al (2014) Sentinel lymph node biopsy versus axillary lymphadenectomy in patients treated with lumpectomy: an analysis of short-term outcomes. Ann Surg Oncol 21(1):74–80. https://doi.org/10.1245/s10434-013-32483 CrossRefPubMed

28.

Verbelen H, Gebruers N, Eckhout F et al (2014) Shoulder and arm morbidity in sentinel node-negative breast cancer patients: a systematic review. Breast Cancer Res Treat 144: 21–31. https://doi.org/10.1007/s10549-014-2846-5

29.

Petrek J, Senie RT, Peters M, Rosen PP (2001) Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 92(6):1368–1377CrossRefPubMed

30.

Lucci A, McCall M, Beitsch M et al (2007) Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLNB alone in the American College of Surgeons oncology group trial Z0011. J Clin Oncol 25:3657–3663. https://doi.org/10.1200/JCO.2006.07.4062 CrossRefPubMed

31.

Francis W, Abghari P, Du W et al (2006) Improving surgical outcomes: standardizing the reporting of incidence and severity of acute lymphedema after sentinel lymph node biopsy and axillary lymph node dissection. Am J Surg 192:363–369. https://doi.org/10.1016/j.amjsurg.2006.08.018 CrossRef

32.

Kootstra JJ, Dijkstra PU, Rietman H et al (2013) A longitudinal study of shoulder and arm morbidity in breast cancer survivors 7 years after sentinel lymph node biopsy or axillary lymph node dissection. Breast Cancer Res Treat 139:125–134. https://doi.org/10.1007/s10549-013-2509-y CrossRefPubMed

Title: Analysis of Undesirable Sequelae of Sentinel Node Surgery in Breast Cancer Patients – a Prospective Cohort Study
Authors: Dominika Kozak
Iwona Głowacka-Mrotek
Tomasz Nowikiewicz
Zygmunt Siedlecki
Wojciech Hagner
Magdalena Sowa
Wojciech Zegarski
Publication date: 01-10-2018
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2018
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-017-0306-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer

Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER−/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact?

Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer

Aspects of Modern Biobank Activity – Comprehensive Review

Knockdown of Sox2 Inhibits OS Cells Invasion and Migration via Modulating Wnt/β-Catenin Signaling Pathway

Incidence of Contrast-Induced Nephropathy in Patients with Multiple Myeloma Undergoing Contrast-Enhanced Procedures

Keynote webinar | Spotlight on antibody–drug conjugates in cancer